Company profile for Diakonos Oncology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

With multiple FDA clinical trials underway, Diakonos Research is redefining the potential of cancer immunotherapy. Studied both in the lab and in the clinical setting, Diakonos has developed revolutionary approaches to Cancer Immunotherapy that have the ability to address a variety of cancer types. Based in the Houston Medical Center, the sole focus of Diakonos is leveraging the body's natural capability of eliminating cancer....
With multiple FDA clinical trials underway, Diakonos Research is redefining the potential of cancer immunotherapy. Studied both in the lab and in the clinical setting, Diakonos has developed revolutionary approaches to Cancer Immunotherapy that have the ability to address a variety of cancer types. Based in the Houston Medical Center, the sole focus of Diakonos is leveraging the body's natural capability of eliminating cancer. Using your immune system combined with our patented treatments, Diakonos has repeatedly demonstrated the ability to activate an immune attack against cancer.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1110 NASA Parkway, Houston, TX 77058, United States
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/diakonos-oncology-to-present-corporate-overview-and-participate-in-panel-at-2026-biotech-showcase-302641688.html

PR NEWSWIRE
15 Dec 2025

https://www.prnewswire.com/news-releases/diakonos-oncology-awarded-multi-million-dollar-research-grant-by-the-cancer-prevention-and-research-institute-of-texas-to-advance-doc1021-in-refractory-melanoma-302637446.html

PR NEWSWIRE
10 Dec 2025

https://www.prnewswire.com/news-releases/diakonos-oncology-presents-promising-preliminary-data-from-phase-1-study-of-doc1021-cell-based-immunotherapy-in-pancreatic-cancer-at-society-for-immunotherapy-of-cancer-40th-annual-meeting-302608210.html

PR NEWSWIRE
07 Nov 2025

https://www.prnewswire.com/news-releases/pancreatic-cancer-clinical-trial-data-for-diakonos-oncologys-doc1021-cell-based-immunotherapy-to-be-presented-at-the-society-for-immunotherapy-of-cancer-sitc-40th-annual-meeting-302594102.html

PR NEWSWIRE
27 Oct 2025

https://www.prnewswire.com/news-releases/diakonos-oncology-announces-first-patient-dosed-in-phase-2-clinical-trial-evaluating-doc1021-dubodencel-for-glioblastoma-302510208.html

PR NEWSWIRE
22 Jul 2025

https://www.prnewswire.com/news-releases/diakonos-oncology-closes-20-million-financing-to-accelerate-phase-2-glioblastoma-clinical-development-program-and-expand-use-of-innovative-dendritic-cell-platform-for-studies-in-other-indications-302468995.html

PR NEWSWIRE
30 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty